March 6, 2025 – Basel, Switzerland / Boston, USA – Roche has announced the launch of the Roche Genentech Innovation Center Boston, a new research hub based at Harvard’s Enterprise Research Campus in Allston. This center will serve as a cutting-edge hub for drug discovery, data science, and artificial intelligence (AI) advancements in cardiovascular, renal, and metabolic diseases (CVRM).
Why This Matters
- Roche will be the first company to establish a presence in Harvard’s Enterprise Research Campus.
- The 30,000-square-foot facility will expand over time, potentially employing up to 500 people.
- The center will integrate expertise in biomedical research, AI-driven drug development, and healthcare innovation.
Strengthening Roche’s Ties with Harvard and the Boston Biotech Ecosystem
Boston is a global life sciences powerhouse, home to some of the world’s top biotech companies, research institutions, and universities. The new innovation center builds on Roche’s longstanding partnership with Harvard, supporting collaboration in disease biology, AI-driven drug discovery, and personalized medicine.
Thomas Schinecker, CEO of Roche, emphasized the importance of this investment:
“By establishing this new center of excellence in Boston, we are harnessing the area’s world-class talent and research capabilities to accelerate drug discovery and innovation. This is part of Roche’s broader commitment to advancing science through collaboration.”
A Hub for Cardiovascular, Renal, and Metabolic Disease Research
The Roche Genentech Innovation Center Boston will focus on:
- Developing new treatments for heart, kidney, and metabolic diseases.
- Expanding Roche’s AI and data science capabilities to enhance drug discovery.
- Supporting collaborations with academic and industry partners in Boston.
Support from Local and State Leaders
Alan Garber, President of Harvard University, highlighted the significance of Roche’s investment:
“When leading biomedical companies and research institutions collaborate, groundbreaking discoveries follow. This center will create new opportunities to advance human health.”
Massachusetts Governor Maura Healey added:
“Massachusetts continues to be a leader in life sciences thanks to innovative partnerships like this one. Roche’s expansion will drive scientific breakthroughs and create high-quality jobs in our state.”
Roche’s Expanding U.S. Presence
With more than 25,000 employees in the U.S., Roche has invested $11 billion in the country over the past decade. The company operates multiple research, manufacturing, and distribution sites across the U.S., with a major presence through Genentech and Roche Diagnostics.
About the Enterprise Research Campus
Harvard’s Enterprise Research Campus (ERC) is designed to foster innovation and collaboration among researchers, biotech companies, and startups. The ERC will include research labs, residential buildings, a hotel, a conference center, and retail spaces, with completion expected in 2026.
Looking Ahead
The Roche Genentech Innovation Center Boston represents a major step forward in Roche’s mission to accelerate drug discovery through cutting-edge science and AI. As research progresses, the center is expected to become a major hub for innovation in cardiovascular, renal, and metabolic diseases, helping to develop new treatments that could improve millions of lives worldwide.
For more information, visit www.roche.com.